PUR1900
Allergic Bronchopulmonary Aspergillosis (ABPA) in Asthma / Cystic Fibrosis
Phase 2Active
Key Facts
Indication
Allergic Bronchopulmonary Aspergillosis (ABPA) in Asthma / Cystic Fibrosis
Phase
Phase 2
Status
Active
Company
About Pulmatrix
Pulmatrix is a clinical-stage biotech focused on developing inhaled therapeutics for serious pulmonary and systemic diseases using its proprietary iSPERSE™ dry powder delivery platform. Its strategy centers on reformulating known drug molecules for inhalation to create new products with potential advantages in speed of onset, efficacy, and patient convenience. Key achievements include advancing its lead candidate, PUR3100 for acute migraine, into Phase 2 clinical development and building a diverse pipeline of 13 candidates. The company aims to leverage its versatile platform through internal development and potential partnerships.
View full company profile